Reading Time: 2 minutes
The rotation from technology stocks to the healthcare sector makes Eli Lilly (LLY) an interesting prospect once again. Technically, Lilly shows up as a clear leader stock, gaining about 3.6% on October 14, while the S&P 500 declined by 1.1%. In contrast, Novo Nordisk is still stuck in a downward trend. I prefer Lilly fundamentally, but I do not see the competition as being settled. With the Wegovy injection and tablet, Novo remains a serious competitor. Factors in favor of Lilly include its immense growth and the breadth of its product offerings....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
